Guided Therapeutics (GTHP) Cash from Investing Activities Growth (1y) (2012 - 2022)
Guided Therapeutics (GTHP) Cash from Investing Activities Growth (1y) (2012 - 2022) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -208.79% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -397.90% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -514.25% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -187.82% |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 25.00% |
| Mar 31, 2022 | -1,300.00% |
| Sep 30, 2021 | -400.00% |
| Dec 31, 2015 | 0.00% |
| Sep 30, 2015 | 92.00% |
| Dec 31, 2014 | -250.00% |
| Sep 30, 2014 | -150.00% |
| Mar 31, 2014 | 96.04% |
| Dec 31, 2013 | 107.14% |
| Sep 30, 2013 | 93.10% |
| Mar 31, 2013 | 22.31% |
| Dec 31, 2012 | 78.13% |
| Sep 30, 2012 | 52.15% |
| Jun 30, 2012 | -190.79% |
| Mar 31, 2012 | -88.41% |